BioprintingCompany VisitsItaly

CELLINK showcases bioprinting progress at the Collaborative Partnership Conference

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Bioprinting company CELLINK is continually striving to advance the possibilities of additive manufacturing in the medical, and specifically bioprinting, field. To highlight its efforts, the company recently hosted a Collaborative Partnership Conference on May 10 in Milan, Italy. The event was the perfect opportunity to showcase the technological solutions offered by the company and, above all, the current use cases for them.

The event was held at the San Raffaele Hospital and brought together various Italian and foreign companies that are using CELLINK’s bioprinters to develop highly innovative research projects. Arguably the most relevant were the case studies shown by the San Raffaele Scientific Institute and by the University of Pavia, the most 3D printing-oriented university in Italy known for opening 3D4Med, the first Clinical 3D Printing Laboratory in Italy and one of the few international companies of its kind.

Collaborative Partnership Conference
The Lumen X 3D bioprinter leverages biocompatible blue light for high resolution tissue printing.

The CELLINK Collaborative Partnership Conference provided a comprehensive overview of the applicability of bioprinting in critical fields such as research for autoimmune diseases treatments and regenerative medicine, with a lot of examples that demonstrate how CELLINK’s systems can help experts to obtain concrete results and more reliability. Most importantly, this general overview of concrete use cases proves that the company’s 3D bioprinting is an important tool for medical and scientific research.

In the end, the Collaborative Partnership Conference was an opportunity to see the Lumen X bioprinter in action. The machine, released in March 2019, was developed for the vascular sector in partnership with Volumetric. Thanks to one million light points, it is capable of bioprinting microscopic features down to 200 microns. With this capability, the Lumen X could mark a real turning point for vascular research, assuring the fast production of complex vascular structures.

[Originally published on Replicatore]

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Matteo Maggioni

Matteo brings extensive experience as a professional tech journalist to 3DPBM’s Italian editorial website, Replicatore. He has been involved since the very beginning, and has continued to cover the AM industry and its many evolutions. He keeps an eye on its potential to reach the consumer target. Matteo lives and works in Milan, Italy and received his degree from Università degli Studi di Milano, Italy.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.